Taylor Robert W
University of Newcastle upon Tyne, Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry, Newcastle upon Tyne, NE2 4HH, UK.
Expert Opin Biol Ther. 2005 Feb;5(2):183-94. doi: 10.1517/14712598.5.2.183.
Despite recent epidemiological studies confirming that mitochondrial respiratory chain disorders due to mutations in either the mitochondrial or nuclear genome are amongst the most common inherited human diseases, realistic therapeutic strategies for these patients remain limited. The disappointing response to various vitamins, cofactors and electron acceptors that have been administered to patients in an attempt to bypass the underlying respiratory chain defect, coupled with the complexities of human mitochondrial genetics, means that novel and innovative means are required to offer realistic treatments. Several 'gene therapy' strategies have therefore been proposed to treat patients with pathogenic mitochondrial DNA mutations, and although these are not without their own inherent problems, several exciting approaches promise much in the near future. This review will provide a basic background to mitochondrial genetics and mitochondrial DNA disorders before introducing the various strategies being tested in vitro at present, in cell culture and animal models, and, in the example of therapeutic exercise, in patients themselves.
尽管最近的流行病学研究证实,由于线粒体或核基因组突变导致的线粒体呼吸链疾病是最常见的人类遗传性疾病之一,但针对这些患者的切实可行的治疗策略仍然有限。向患者施用各种维生素、辅因子和电子受体以试图绕过潜在的呼吸链缺陷,但反应令人失望,再加上人类线粒体遗传学的复杂性,这意味着需要新颖创新的方法来提供切实可行的治疗方案。因此,已经提出了几种“基因疗法”策略来治疗患有致病性线粒体DNA突变的患者,尽管这些策略也有其自身固有的问题,但有几种令人兴奋的方法在不久的将来有望取得很大进展。在介绍目前正在体外、细胞培养和动物模型中测试的各种策略之前,以及以治疗性运动为例介绍在患者自身中测试的策略之前,本综述将提供线粒体遗传学和线粒体DNA疾病的基本背景知识。